Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy

The management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten. Unlike traditional pharmacotherapy, which primarily addresses symptoms, CMIs target the underlying mechanism of sarcomeric hyperco...

Description complète

Détails bibliographiques

Auteurs principaux:	Benedetto Ferraresi, Antonio Nenna, Mohamad Jawabra, Diletta Corrado, Andrea Faggiano, Stefano Carugo, Carmelo Dominici, Giovanni Casali, Massimo Chello, Mario Lusini
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2026-04-01
Collection:	Journal of Cardiovascular Development and Disease
Sujets:	hypertrophic cardiomyopathy cardiac myosin inhibitors mavacamten septal reduction therapy surgical myectomy
Accès en ligne:	https://www.mdpi.com/2308-3425/13/5/187
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!